The significant association between <i>TERT</i>p and <i>TP53</i> mutations was independently validated in a separate cohort.<h4>Conclusions</h4>Bladder urothelial cancer can be stratified into biologically and clinically distinct subtypes on the basis of cancer driver mutations, with concomitant <i>TERT</i>p/<i>TP53</i> nucleotide changes strongly linked to reduced patients' overall survival. This evidence concerns the gene TERT and bladder transitional cell carcinoma.